Oral Vancomycin for Clostridioides difficile Infection
For initial C. difficile infection, use oral vancomycin 125 mg four times daily for 10 days; this is the standard dose that is equally effective as higher doses and should not be exceeded unless treating fulminant disease. 112
Dosing by Clinical Presentation
Initial CDI Episode
- Standard dose: 125 mg orally four times daily for 10 days 112
- This is the FDA-approved dose and guideline-recommended alternative to fidaxomicin 122
- Research confirms 125 mg is as effective as 500 mg doses with no difference in clinical outcomes, duration of diarrhea (4-5 days), or recurrence rates 34
First Recurrence
- Tapered and pulsed regimen: 125 mg four times daily for 10-14 days, then twice daily for 7 days, then once daily for 7 days, then every 2-3 days for 2-8 weeks 11
- Alternative: Standard 125 mg four times daily for 10 days if metronidazole was used initially 1
Fulminant CDI (Hypotension, Ileus, Megacolon)
- High-dose: 500 mg orally four times daily 11
- Add rectal vancomycin instillation if ileus present 1
- Combine with IV metronidazole 500 mg every 8 hours 1
Common Side Effects
Oral vancomycin is remarkably well-tolerated with minimal systemic absorption in most patients. 23
Gastrointestinal Effects
- Abdominal discomfort
- Nausea
- Flatulence
- These are generally mild and reported infrequently 5
Serious but Rare Adverse Events
Nephrotoxicity is the most clinically significant concern:
- Can occur during or after treatment completion 2
- Risk is substantially increased in patients >65 years of age 2
- Monitor renal function during and after treatment in elderly patients, even those with normal baseline function 2
- Renal impairment, elevated creatinine, and renal failure have been reported in clinical trials 2
Ototoxicity (extremely rare):
- Tinnitus, hearing loss, sensation of "buzzing" or "clogged ears" 6
- Related to systemic absorption in patients with compromised intestinal mucosa 26
- Usually resolves with dose reduction or discontinuation 6
Systemic Absorption Risk Factors
Measurable serum concentrations can occur in specific situations 2:
- Active C. difficile-associated diarrhea with inflammatory bowel disease
- Renal insufficiency
- Severe colitis with compromised intestinal barrier 26
Monitor serum vancomycin levels in these high-risk patients, particularly if receiving concomitant aminoglycosides 2
Critical Clinical Pearls
Dosing Pitfalls to Avoid
- Do not routinely use 250 mg or 500 mg doses for non-fulminant CDI - no evidence of superior efficacy and increases cost unnecessarily 34
- Higher doses (≥250 mg four times daily) show no difference in recurrence, clinical failure, mortality, or readmission compared to standard 125 mg dosing 4
- Fecal vancomycin levels with 125 mg dosing are still 3 orders of magnitude higher than the MIC90 against C. difficile 7
Special Considerations
- Recurrence occurs in 18-25% of patients regardless of dose 25
- Oral vancomycin is NOT systemically absorbed in most patients and is NOT effective for other infections 22
- Must be given orally; IV vancomycin is ineffective for CDI 22
- In patients with very severe diarrhea (≥4 stools daily), consider a loading approach of 250 mg for the first 24-48 hours, then reduce to standard 125 mg to ensure adequate fecal levels initially 7
Monitoring Requirements
For patients >65 years old or with risk factors for systemic absorption:
- Baseline renal function
- Monitor creatinine during treatment
- Follow-up renal function after completion 2